Stem cells are one of the most exciting areas of biotechnology. And now, there’s a startup that wants to see if artificial intelligence can help advance breakthroughs for stem cell based therapeutics.
What’s happening:
- Artificial intelligence biotechnology startup CellVoyant has raised €7.6M in a seed round
- The round saw participation from multiple notable venture funds including Octopus Ventures, Horizons Ventures, Verve Ventures and others
The big idea:
- CellVoyant is leveraging artificial intelligence and computer vision to develop new stem cell based therapeutics for chronic diseases
- By using live imaging of stem cells, CellVoyant is aiming to be to controllably manufacture any cell or tissue in the body at scale
- One of the biggest challenges in stem cell therapies is how unpredictable stem cell biology is, which CellVoyant is aiming to change by using technology to better understand precisely how cells are composed and how they evolve
Why it matters:
- Stem cell treatments have shown enormous therapeutic potential for helping to repair diseased or injured tissue in the body and has unlocked promising new treatment possibilities for both cancer and diabetes
- Many scientists and researchers are currently exploring stem cells as a potential treatment for dementia, infertility and spinal cord injuries
The intrigue:
- CellVoyant is a spin out from the University of Bristol and leverages research that was done at the University of Bristol’s School Of Cellular and Molecular Medicine
